N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease
Abstract
Patients with hypertensive heart disease have elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The aim of our study was to evaluate NT-proBNP in patients with long-standing hypertension and in patients with signs of hypertensive cardiomyopathy. The study included three groups of 50 subjects: healthy persons (Control Group), patients with hypertension and normal left ventricular systolic function (Group 1) and patients with long-standing hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (Group 2). Our results show a very good correlation (Pearson's test) between NT-proBNP in Group 1 and Group 2 and C-reactive protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856), diastolic blood pressure (Group 1: r = 0.4282; Group 2: r = 0.3989) and ejection fraction (Group 1: r = -0.7390; Group 2: r = 0.9111). ROC analysis revealed that the AUC between ...the Control Group and Group 1 for NT-proBNP (0.912) was not significantly different (p>0.05) from the AUC for systolic (0.924) and diastolic pressure (0.937). A cut-off value for NT-proBNP of 5.89 pmol/L can be used to reliably distinguish patients of Group 1 from the Control Group, and a cut-off value of 21.67 pmol/L reliably separates patients from Group 1 and Group 2 (in both cases, the AUC is 1.000). Patients in Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those in NYHA class I (ANOVA test, p=0.001). These data suggest that NT-proBNP is a useful biomarker for distinguishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients.
Keywords:
N-terminal pro-B-type natriuretic peptide / hypertensive heart disease / hypertensive cardiomyopathySource:
Journal of Medical Biochemistry, 2011, 30, 3, 244-249Publisher:
- Društvo medicinskih biohemičara Srbije, Beograd i Versita
Funding / projects:
- Biomarkers of organ damage and dysfunction (RS-175036)
DOI: 10.2478/v10011-011-0016-4
ISSN: 1452-8258
WoS: 000292419300010
Scopus: 2-s2.0-79959535160
Collections
Institution/Community
PharmacyTY - JOUR AU - Pejović, Janko AU - Ignjatović, Svetlana AU - Dajak, Marijana AU - Majkić-Singh, Nada AU - Vučinić, Žarko PY - 2011 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1557 AB - Patients with hypertensive heart disease have elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The aim of our study was to evaluate NT-proBNP in patients with long-standing hypertension and in patients with signs of hypertensive cardiomyopathy. The study included three groups of 50 subjects: healthy persons (Control Group), patients with hypertension and normal left ventricular systolic function (Group 1) and patients with long-standing hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (Group 2). Our results show a very good correlation (Pearson's test) between NT-proBNP in Group 1 and Group 2 and C-reactive protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856), diastolic blood pressure (Group 1: r = 0.4282; Group 2: r = 0.3989) and ejection fraction (Group 1: r = -0.7390; Group 2: r = 0.9111). ROC analysis revealed that the AUC between the Control Group and Group 1 for NT-proBNP (0.912) was not significantly different (p>0.05) from the AUC for systolic (0.924) and diastolic pressure (0.937). A cut-off value for NT-proBNP of 5.89 pmol/L can be used to reliably distinguish patients of Group 1 from the Control Group, and a cut-off value of 21.67 pmol/L reliably separates patients from Group 1 and Group 2 (in both cases, the AUC is 1.000). Patients in Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those in NYHA class I (ANOVA test, p=0.001). These data suggest that NT-proBNP is a useful biomarker for distinguishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients. PB - Društvo medicinskih biohemičara Srbije, Beograd i Versita T2 - Journal of Medical Biochemistry T1 - N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease VL - 30 IS - 3 SP - 244 EP - 249 DO - 10.2478/v10011-011-0016-4 ER -
@article{ author = "Pejović, Janko and Ignjatović, Svetlana and Dajak, Marijana and Majkić-Singh, Nada and Vučinić, Žarko", year = "2011", abstract = "Patients with hypertensive heart disease have elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The aim of our study was to evaluate NT-proBNP in patients with long-standing hypertension and in patients with signs of hypertensive cardiomyopathy. The study included three groups of 50 subjects: healthy persons (Control Group), patients with hypertension and normal left ventricular systolic function (Group 1) and patients with long-standing hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (Group 2). Our results show a very good correlation (Pearson's test) between NT-proBNP in Group 1 and Group 2 and C-reactive protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856), diastolic blood pressure (Group 1: r = 0.4282; Group 2: r = 0.3989) and ejection fraction (Group 1: r = -0.7390; Group 2: r = 0.9111). ROC analysis revealed that the AUC between the Control Group and Group 1 for NT-proBNP (0.912) was not significantly different (p>0.05) from the AUC for systolic (0.924) and diastolic pressure (0.937). A cut-off value for NT-proBNP of 5.89 pmol/L can be used to reliably distinguish patients of Group 1 from the Control Group, and a cut-off value of 21.67 pmol/L reliably separates patients from Group 1 and Group 2 (in both cases, the AUC is 1.000). Patients in Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those in NYHA class I (ANOVA test, p=0.001). These data suggest that NT-proBNP is a useful biomarker for distinguishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients.", publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita", journal = "Journal of Medical Biochemistry", title = "N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease", volume = "30", number = "3", pages = "244-249", doi = "10.2478/v10011-011-0016-4" }
Pejović, J., Ignjatović, S., Dajak, M., Majkić-Singh, N.,& Vučinić, Ž.. (2011). N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease. in Journal of Medical Biochemistry Društvo medicinskih biohemičara Srbije, Beograd i Versita., 30(3), 244-249. https://doi.org/10.2478/v10011-011-0016-4
Pejović J, Ignjatović S, Dajak M, Majkić-Singh N, Vučinić Ž. N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease. in Journal of Medical Biochemistry. 2011;30(3):244-249. doi:10.2478/v10011-011-0016-4 .
Pejović, Janko, Ignjatović, Svetlana, Dajak, Marijana, Majkić-Singh, Nada, Vučinić, Žarko, "N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease" in Journal of Medical Biochemistry, 30, no. 3 (2011):244-249, https://doi.org/10.2478/v10011-011-0016-4 . .